Mastering Revenue Cycle Management: The Key to Thriving in Dallas-Fort Worth’s Healthcare Boom

 

In an episode of Highway to Health shot at the iconic Billy Bob’s, David Kemp and healthcare veteran Kelly Strong dissected Dallas-Fort Worth’s evolution into a healthcare powerhouse, fueled by rapid population increases and a business-friendly environment. During the enlightening conversation, Strong highlighted the importance of mastering revenue cycle management and identified it as the cornerstone of DFW’s healthcare sector growth.

Strong, who currently serves as the Senior Vice President of Healthcare Operations, Revenue Cycle Improvement, underlined how DFW has not only attracted healthcare providers and startups but has also become a fertile ground for technological advancements in patient care. While outlining the challenges healthcare providers face, such as managing denials and integrating disparate technological systems, Strong’s narrative underscored the necessity of mastering revenue cycle management and adopting comprehensive strategies to ensure financial stability and foster patient trust.

Article written by MarketScale.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…